162 related articles for article (PubMed ID: 38178263)
1. Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Zhou Q; Zhang J; Zhang J; Liang S; Cai D; Xiao H; Zhu Y; Xiang W; Rodrigues-Lima F; Chi J; Guidez F; Wang L
Biol Direct; 2024 Jan; 19(1):6. PubMed ID: 38178263
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
[TBL] [Abstract][Full Text] [Related]
3. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
[TBL] [Abstract][Full Text] [Related]
4. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib sensitizes thyroid cancer to BRAF inhibitor
Tsumagari K; Abd Elmageed ZY; Sholl AB; Green EA; Sobti S; Khan AR; Kandil A; Murad F; Friedlander P; Boulares AH; Kandil E
Endocr Relat Cancer; 2018 Jan; 25(1):99-109. PubMed ID: 29269566
[TBL] [Abstract][Full Text] [Related]
7. Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
10. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of
Jiang M; Chen Y; Deng L; Luo X; Wang L; Liu L
DNA Cell Biol; 2019 May; 38(5):476-484. PubMed ID: 30835546
[TBL] [Abstract][Full Text] [Related]
12. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
13. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
14. Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia.
Byrd JC; Edenfield WJ; Dow NS; Aylesworth C; Dawson N
Leuk Lymphoma; 1996 Mar; 21(1-2):153-9. PubMed ID: 8907283
[TBL] [Abstract][Full Text] [Related]
15. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
He X; Dou A; Feng S; Roman-Rivera A; Hawkins C; Lawley L; Zhang J; Wunderlich M; Mizukawa B; Halene S; Patel A; Fang J
Exp Hematol; 2020 Jun; 86():21-27.e2. PubMed ID: 32437909
[TBL] [Abstract][Full Text] [Related]
17. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
18. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
[TBL] [Abstract][Full Text] [Related]
19. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
20. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
